Atherosclerosis
Volume 192, Issue 2 , Pages 235-242, June 2007

Screening patients for subclinical atherosclerosis with non-contrast cardiac CT

  • Reza Ardehali

      Affiliations

    • Stanford Hospital, Division of Cardiovascular Medicine, Stanford, CA, United States
    • Corresponding Author InformationCorresponding author at: Division of Cardiovascular Medicine, Stanford University School of Medicine, 300 Pasteur Drive, H-2157 Stanford, CA 94305-5233, United States. Tel.: +1 650 723 8138; fax: +1 650 724 4034.
  • ,
  • Khurram Nasir

      Affiliations

    • Massachusetts General Hospital Cardiac MRI, PET, CT Program, Boston, MA, United States
  • ,
  • Aravindan Kolandaivelu

      Affiliations

    • Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore, MD, United States
  • ,
  • Matthew J. Budoff

      Affiliations

    • UCLA Division of Cardiology, Torrance, CA, United States
  • ,
  • Roger S. Blumenthal

      Affiliations

    • Johns Hopkins Ciccarone Preventive Cardiology Center, Baltimore, MD, United States

Received 15 June 2006; received in revised form 16 January 2007; accepted 16 March 2007. published online 10 May 2007.

Abstract 

Accurate risk assessment may be helpful in decreasing cardiovascular events through more appropriate targeting of preventive measures. Traditional risk assessment may be refined with the selective use of coronary artery calcium score (CACS) or other methods of subclinical atherosclerosis measurement. This article reviews information pertaining to the clinical use of CACS for assessing coronary atherosclerosis as a useful predictor of coronary artery disease (CAD) in certain population of patients. Coronary calcification is a marker of atherosclerosis that can be quantified with the use of cardiac CT and it is proportional to the extent and severity of atherosclerotic disease. The published studies demonstrate a high sensitivity of CACS for the presence of coronary artery disease but a much lower specificity for obstructive CAD depending on the magnitude of the CACS. Several large clinical trials have found clear, incremental predictive value of CACS over the Framingham risk score when used in asymptomatic patients. However, early detection of CAD by Electron Beam Tomography (EBT) screening has not convincingly demonstrated a reduction in mortality and morbidity. Nevertheless, relevant prognostic information obtained may be useful to initiate or intensify appropriate treatment strategies to slow the progression of existing atherosclerotic vascular disease. Current data suggest intermediate-risk patients may benefit most from further risk stratification with cardiac CT, as CAC testing is effective at identifying increased risk and in one study motivating effective behavioral changes. Randomized clinical trials will help determine if selective use of cardiac CT in the intermediate-risk patient would lead to more appropriate use of pharmacologic therapy and improved clinical outcomes.

Keywords: Coronary calcification, Asymptomatic coronary artery disease, Subclinical atherosclerosis, Coronary artery disease risk assessment, Electron beam computed tomography (EBCT)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(07)00189-X

doi:10.1016/j.atherosclerosis.2007.03.022

Atherosclerosis
Volume 192, Issue 2 , Pages 235-242, June 2007